Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Fennec Pharmaceuticals Inc

Healthcare CA FRX

9.87CAD
-0.48(4.64%)

Last update at 2026-03-09T14:52:00Z

Day Range

9.879.87
LowHigh

52 Week Range

7.0213.83
LowHigh

Fundamentals

  • Previous Close 10.35
  • Market Cap361.29M
  • Volume4
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.32700M
  • Revenue TTM38.79M
  • Revenue Per Share TTM1.41
  • Gross Profit TTM 36.12M
  • Diluted EPS TTM-0.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -0.07100M -16.04500M -23.71400M -17.34600M -18.10900M
Minority interest - - - - -
Net income -0.43600M -16.04500M -23.86100M -17.36500M -17.83100M
Selling general administrative 23.05M 20.59M 17.72M 12.24M 12.95M
Selling and marketing expenses 18.43M 12.12M 2.79M - -
Gross profit 44.35M 19.99M 1.45M - 0.17M
Reconciled depreciation 0.80M 0.29M - 0.02M 0.40M
Ebit 4.00M -12.93800M -22.58900M -17.22300M -17.88500M
Ebitda 4.80M -12.65100M -22.54300M -17.18500M -17.98500M
Depreciation and amortization 0.80M 0.29M 0.05M 0.04M -0.10000M
Non operating income net other - - - - -
Operating income 2.57M -12.77100M -22.58900M -17.22300M -17.88500M
Other operating expenses 44.97M 34.02M 24.12M 17.22M 18.05M
Interest expense 4.07M 3.39M 0.98M 0.13M 0.00000M
Tax provision 0.36M 0.00000M - - -
Interest income 2.64M 0.44M 0.20M 0.12M 0.09M
Net interest income -2.47600M -2.95300M -0.93200M -0.07200M -0.31500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.36M 3.39M 0.15M 0.02M -0.27800M
Total revenue 47.54M 21.25M 1.53M 0.00000M 0.17M
Total operating expenses 41.79M 32.76M 24.04M 17.22M 18.05M
Cost of revenue 3.18M 1.26M 0.09M - -
Total other income expense net -2.63900M -3.27400M -1.12500M -0.12300M -0.22400M
Discontinued operations - - - - -
Net income from continuing ops -0.43600M -16.04500M -23.71400M -17.34600M -18.10900M
Net income applicable to common shares -0.43600M -16.04500M -23.71400M -17.34600M -18.10900M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 44.95M 26.86M 26.94M 22.41M 31.42M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.47M 0.04M 0.06M 0.25M 0.28M
Total liab 50.82M 38.49M 29.51M 6.64M 2.35M
Total stockholder equity -5.87200M -11.62200M -2.56900M 15.77M 29.07M
Deferred long term liab - - 0.21M 0.03M -
Other current liab - 3.75M 2.22M 0.88M 0.78M
Common stock - 144.31M 142.59M 140.80M 140.73M
Capital stock 145.61M 144.31M 142.59M 140.80M 140.73M
Retained earnings -219.68100M -219.24500M -203.20000M -179.48600M -162.14000M
Other liab - - 0.26M 4.99M -
Good will - - - - -
Other assets - - 0.21M 0.03M 0.00000M
Cash 26.63M 13.27M 23.77M 21.10M 30.34M
Cash and equivalents - - 23.77M 21.10M 30.34M
Total current liabilities 6.92M 7.55M 4.61M 1.65M 2.35M
Current deferred revenue - - - - -
Net debt - 17.68M 1.12M -16.11200M -30.34400M
Short term debt - 0.02M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - 30.95M 24.90M 4.99M -
Other stockholder equity - 62.07M 56.80M 53.21M 49.23M
Property plant equipment - - - - -
Total current assets 44.12M 26.86M 26.73M 22.39M 31.42M
Long term investments - - - - -
Net tangible assets - - -2.56900M 15.77M 29.07M
Short term investments - - - - -
Net receivables 12.88M 8.81M 1.54M - -
Long term debt 19.34M 30.93M 24.90M 5.00M -
Inventory 1.06M 2.16M 0.58M - -
Accounts payable 3.24M 3.78M 2.39M 0.78M 1.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 1.24M 1.24M 1.24M 1.24M
Additional paid in capital - - - - -
Common stock total equity - - - - 140.73M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.82M 0.00600M - 0.03M -
Deferred long term asset charges - - - - -
Non current assets total 0.82M 0.00600M 0.21M 0.03M 0.00000M
Capital lease obligations 0.00200M 0.02M - - -
Long term debt total - - 25.00M 5.00M 0.00000M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - - - -
Change to liabilities - - 1.61M -0.79400M -0.04100M
Total cashflows from investing activities - - - - -
Net borrowings -13.00000M 5.00M 20.17M 4.99M 4.99M
Total cash from financing activities -13.61500M 6.64M 20.73M 4.98M 32.29M
Change to operating activities - - 1.61M -0.13800M -0.62200M
Net income -0.43600M -16.04500M -23.71400M -17.34600M -18.10900M
Change in cash 13.37M -10.50500M 2.67M -9.24400M 16.69M
Begin period cash flow 13.27M 23.77M 21.10M 30.34M 13.65M
End period cash flow 26.63M 13.27M 23.77M 21.10M 30.34M
Total cash from operating activities 26.98M -17.14300M -18.05800M -14.22200M -15.59500M
Issuance of capital stock - - - 0.00000M 31.97M
Depreciation 0.80M 0.00000M - 0.02M -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.58M -1.58000M -0.57600M -0.57600M -0.57600M
Change to account receivables -7.87300M -7.26900M -1.54500M -1.54500M -1.54500M
Sale purchase of stock -0.17600M -0.07800M 0.93M 0.03M 32.29M
Other cashflows from financing activities -0.43900M 1.64M 25.73M 4.98M 0.32M
Change to netincome - - 4.40M 4.04M 2.77M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 16.94M -6.77800M 1.10M -0.93200M -0.76300M
Stock based compensation 5.06M 5.35M 4.09M 3.75M 2.79M
Other non cash items 4.61M 0.33M 0.47M 0.31M 0.49M
Free cash flow 26.98M -17.14300M -18.05800M -14.22200M -15.59500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FRX
Fennec Pharmaceuticals Inc		 -0.48 4.64% 9.87 - 11.59 9.31 57.98 6.52 20.27
EPRX
Eupraxia Pharmaceuticals Inc		 0.21 1.97% 10.86 - - - 7.79 -3.8823
MSCL
Satellos Bioscience Inc.		 -2.98 18.90% 12.79 4.81 - - 5.61 6.47
HBP
Helix BioPharma Corp.		 0.10 5.41% 1.95 - - - 8.70 -6.3589
MDNA
Medicenna Therapeutics Corp		 0.02 2.33% 0.88 - 204.08 - 7.00 -6.1093

Reports Covered

Stock Research & News

View All

Profile

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc

68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709

Key Executives

Name Title Year Born
Mr. Rostislav Raykov CEO & Director 1976
Mr. Robert C. Andrade Chief Financial Officer 1975
Mr. Mark Meier Sr. VP of Commercial NA
Mr. Mark Gowland Controller NA
Mr. Lei Fang Pres of Pharstat Inc NA
Ms. Anne McKay Regulatory Consultant 1954
Mr. Alexander D. Smith M.S. Consultant NA
Mr. Terry Evans Chief Commercial Officer NA
Dr. Pierre S. Sayad M.S., Ph.D. Chief Medical Officer NA
Ms. Christiana Cioffi M.B.A. Chief Strategy Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.